拉米夫定联合小剂量乙肝免疫球蛋白预防肝移植术后HBV再感染的临床分析  

Clinical Analysis of Lamivudine Combined with Low-Dose Hepatitis B Immune Globulin to Prevent HBV Reinfection after Liver Transplantation

作　　者：袁伟升[1] 宫琳[1] 刘鹏[1] 矫学黎[1] 郭大伟[1] 王鹏[1] 

机构地区：[1]中国人民解放军济南军区第401医院肝胆外科,山东青岛266071

出　　处：《中国普外基础与临床杂志》2015年第4期451-454,共4页Chinese Journal of Bases and Clinics In General Surgery

摘　　要：目的探讨拉米夫定联合小剂量乙肝免疫球蛋白预防肝移植术后HBV再感染的效果。方法回顾性分析76例HBV相关性肝病患者肝移植术后采用拉米夫定联合小剂量乙肝免疫球蛋白预防HBV再感染的临床资料,分析HBV再感染的危险因素。结果 76例患者术后HBs Ag转为阴性,HBV再感染9例,术后1年内HBV再感染率为9.2%(7/76),2年内再感染率11.8%(9/76)。结论拉米夫定与小剂量乙肝免疫球蛋白联合应用可有效地预防肝移植术后HBV的再感染,肝移植术前HBe Ag阳性及HBV-DNA阳性是HBV再感染的危险因素。Objective To investigate the efficacy of lamivudine combined with low-dose hepatitis B immune globulin to prevent HBV reinfection after liver transplantation. Methods The clinical data of 76 cases of HBV-related liver disease after liver transplantation using lamivudine combined with low-dose hepatitis B immune globulin to prevent HBV re-infection were retrospectively analyzed, and the HBV re-infection risk factors were analyzed. Results Seventysix patients＇ HBs Ag became negative after liver transplantation, HBV re-infect in 9 cases. The re-infection rate was 9.2%（7/76） and 11.8%（9/76）, respectively, in 1-year and 2-year after liver transplantation. Conclusions Lamivudine combined with low-dose hepatitis B immune globulin after liver transplantation can be effective preventing re-infection with HBV. HBe Ag positive and HBV-DNA positive before liver transplantation is risk factors of HBV re-infection.

关 键 词：肝移植 乙型肝炎病毒 乙肝免疫球蛋白 拉米夫定 

分 类 号：R657.3[医药卫生—外科学]